According to the UK product information, no dose adjustment is required for patients with renal or hepatic impairment, or based on age or body weight, as these factors have no clinically relevant effect on semaglutide's pharmacokinetics
I think there is no doubt this will elevate GLP-1 receptor agonists in the treatment paradigm, perhaps even above SGLT2 inhibitors, because the benefit on mortality is substantial, Pratley told Healio | Endocrine Today
The medication helps reduce cravings for sugar and alcohol, both of which increase results.
Clinical data shows average A1C reduction of 2.02% in participants with diabetes, triglyceride reduction of 28%, systolic blood pressure reduction of 6.8mmHg, and LDL cholesterol reduction of 12%
The study found that in the initial unadjusted population, those taking tirzepatide and semaglutide differed
11 Diabetes, Obesity and Metabolism GI tolerability of incretin therapiesReview of gastrointestinal side effects (nausea, GI discomfort) of GLP-1-based therapies and titration strategies